Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 6/2013

01-12-2013 | Viewpoint

Refining the role of BRCA1 in combating oxidative stress

Author: Jeffrey R Marks

Published in: Breast Cancer Research | Issue 6/2013

Login to get access

Abstract

The BRCA1 hereditary susceptibility gene has been studied in great depth, befitting its clear role in promoting basal type breast cancer and serous type ovarian (fallopian tube) cancer in women carrying germline mutations. The BRCA1 protein has long been implicated in maintaining genome integrity through DNA repair processes. However, a number of studies have demonstrated that BRCA1 is also involved in the response to oxidative stress. A recent paper by Gorrini and colleagues extends our mechanistic understanding of how BRCA1 regulates this pathway. The relative contribution of this activity in BRCA1-associated tumorigenesis and DNA damage response remains unknown.
Literature
1.
Lakhani SR, Manek S, Penault-Llorca F, Flanagan A, Arnout L, Merrett S, McGuffog L, Steele D, Devilee P, Klijn JG, Meijers-Heijboer H, Radice P, Pilotti S, Nevanlinna H, Butzow R, Sobol H, Jacquemier J, Lyonet DS, Neuhausen SL, Weber B, Wagner T, Winqvist R, Bignon YJ, Monti F, Schmitt F, Lenoir G, Seitz S, Hamman U, Pharoah P, Lane G, et al: Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res. 2004, 10: 2473-2481. 10.1158/1078-0432.CCR-1029-3.CrossRefPubMed
2.
Lee E, McKean-Cowdin R, Ma H, Spicer DV, Van Den Berg D, Bernstein L, Ursin G: Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J Clin Oncol. 2011, 29: 4373-4380. 10.1200/JCO.2010.33.6446.CrossRefPubMedPubMedCentral
3.
Johnson N, Johnson SF, Yao W, Li YC, Choi YE, Bernhardy AJ, Wang Y, Capelletti M, Sarosiek KA, Moreau LA, Chowdhury D, Wickramanayake A, Harrell MI, Liu JF, D'Andrea AD, Miron A, Swisher EM, Shapiro GI: Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proc Natl Acad Sci U S A. 2013, 110: 17041-17046. 10.1073/pnas.1305170110.CrossRefPubMedPubMedCentral
4.
Nguyen T, Nioi P, Pickett CB: The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem. 2009, 284: 13291-13295. 10.1074/jbc.R900010200.CrossRefPubMedPubMedCentral
5.
Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K, Asamura H, Yamamoto M, Hirohashi S: Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci U S A. 2008, 105: 13568-13573. 10.1073/pnas.0806268105.CrossRefPubMedPubMedCentral
6.
Bae I, Fan S, Meng Q, Rih JK, Kim HJ, Kang HJ, Xu J, Goldberg ID, Jaiswal AK, Rosen EM: BRCA1 induces antioxidant gene expression and resistance to oxidative stress. Cancer Res. 2004, 64: 7893-7909. 10.1158/0008-5472.CAN-04-1119.CrossRefPubMed
7.
Gorrini C, Baniasadi PS, Harris IS, Silvester J, Inoue S, Snow B, Joshi PA, Wakeham A, Molyneux SD, Martin B, Bouwman P, Cescon DW, Elia AJ, Winterton-Perks Z, Cruickshank J, Brenner D, Tseng A, Musgrave M, Berman HK, Khokha R, Jonkers J, Mak TW, Gauthier ML: BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. J Exp Med. 2013, 210: 1529-1544. 10.1084/jem.20121337.CrossRefPubMedPubMedCentral
8.
Saha T, Rih JK, Rosen EM: BRCA1 down-regulates cellular levels of reactive oxygen species. FEBS Lett. 2009, 583: 1535-1543. 10.1016/j.febslet.2009.04.005.CrossRefPubMedPubMedCentral
9.
Martinez-Outschoorn UE, Balliet R, Lin Z, Whitaker-Menezes D, Birbe RC, Bombonati A, Pavlides S, Lamb R, Sneddon S, Howell A, Sotgia F, Lisanti MP: BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies. Cell Cycle. 2012, 11: 4402-4413. 10.4161/cc.22776.CrossRefPubMedPubMedCentral
10.
11.
Ma J, Cai H, Wu T, Sobhian B, Huo Y, Alcivar A, Mehta M, Cheung KL, Ganesan S, Kong AN, Zhang DD, Xia B: PALB2 interacts with KEAP1 to promote NRF2 nuclear accumulation and function. Mol Cell Biol. 2012, 32: 1506-1517. 10.1128/MCB.06271-11.CrossRefPubMedPubMedCentral
12.
De Lorenzo SB, Patel AG, Hurley RM, Kaufmann SH: The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells. Front Oncol. 2013, 3: 228-CrossRefPubMedPubMedCentral
13.
Woods NT, Mesquita RD, Sweet M, Carvalho MA, Li X, Liu Y, Nguyen H, Thomas CE, Iversen ES, Marsillac S, Karchin R, Koomen J, Monteiro AN: Charting the landscape of tandem BRCT domain-mediated protein interactions. Sci Signal. 2012, 5: rs6-CrossRefPubMedPubMedCentral
Metadata
Title
Refining the role of BRCA1 in combating oxidative stress
Author
Jeffrey R Marks
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 6/2013
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3583

Other articles of this Issue 6/2013

Breast Cancer Research 6/2013 Go to the issue

Research article

Mammographic density and risk of breast cancer by age and tumor characteristics

Research article

A mammosphere formation RNAi screen reveals that ATG4A promotes a breast cancer stem-like phenotype

Letter

RAD51Cdeletion screening identifies a recurrent gross deletion in breast cancer and ovarian cancer families

Research article

Cytochrome P450 2E1 (CYP2E1) regulates the response to oxidative stress and migration of breast cancer cells

Research article

Lapatinib–induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors

Research article

Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits